Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.68 |
| ▸ | NPC1 | O15118 | 8/20 | 0.68 |
| ▸ | MAPT | P10636 | 7/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.68 |
| ▸ | MEN1 | O00255 | 5/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.65 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.65 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.62 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.61 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.61 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.61 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.61 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.61 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.51 |
| ▸ | GAA | P10253 | 5/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12297745 | 0.91 | PSEN1 (0.62) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL12298224 | 0.89 | MEN1 (0.69) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL8296776 | 0.88 | CYP1A1 (0.65) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL12297984 | 0.88 | ESR1 (0.68) | NPC1MAPTKMT2AMEN1CYP1A2 | |
| SCHEMBL10072683 | 0.88 | CYP1A1 (0.65) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL12297890 | 0.88 | CYP1A1 (0.65) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL8296712 | 0.87 | PTGS2 (0.71) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL12298043 | 0.87 | CYP1A1 (0.61) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL12297885 | 0.87 | PSEN1 (0.63) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL12298333 | 0.85 | PSEN1 (0.75) | RAB9ANPC1MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119680-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8017629-B2 | Compounds and uses thereof in modulating amyloid β | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100331551-A1 | ALPHA-HALOKETONE DERIVATIVES OF IMIDAZOLYL-SUBSTITUTED AROMATIC COMPOUNDS AND COMPOUNDS PREPARED THEREFROM | NEUROGENETIC PHARMACEUTICALS, INC | 2010-12-30 | — | — | US | disclosed |
| US-20100324032-A1 | COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | disclosed |
| US-7799808-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7781442-B2 | Compounds and uses thereof in modulating amyloid beta | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | TORREYPINES THERAPEUTICS INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | TORREYPINES THERAPEUTICS INC. | 2007-10-25 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324032-A1 | COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA | APP, BACE1, BACE2 | RAB9A 2158/4885NPC1 61/4885MAPT 10/4885 |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | APP, BACE1, BACE2 | RAB9A 2158/4885NPC1 61/4885MAPT 10/4885 |
| US-20100331551-A1 | ALPHA-HALOKETONE DERIVATIVES OF IMIDAZOLYL-SUBSTITUTED AROMATIC COMPOUNDS AND COMPOUNDS PREPARED THEREFROM | HYPK, APP, NEFM | RAB9A 3673/4885NPC1 229/4885MAPT 7/4885 |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | PSEN2, APP, BACE1 | RAB9A 2805/4885NPC1 719/4885MAPT 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.